Clinical trial · no report yet · Phase 1/Phase 2
NCT03989414
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
- NCT03989414 ↗
- Active, not recruiting
- Celgene
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 48 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- CC-92480; Bortezomib; Dexamethasone; Daratumumab; Carfilzomib; Elotuzumab; Isatuximab; Carfilzomib
- Arms
- Cohort A: CC-92480 with bortezomib and dexamethasone · Experimental
- Cohort C: CC-92480 with carfilzomib and dexamethasone · Experimental
- Cohort H: CC-92480 with elotuzumab and dexamethasone · Experimental
- Cohort I: CC-92480 with isatuximab and dexamethasone · Experimental
- Cohort D: CC-92480 with bortezomib and dexamethasone · Experimental
- Cohort F: CC-92480 with carfilzomib and dexamethasone · Experimental
- Cohort J: CC-92480 with elotuzumab and dexamethasone · Experimental
- Cohort K: CC-92480 with isatuximab and dexamethasone · Experimental
- Cohort G: CC-92480 with bortezomib and dexamethasone · Experimental
- Subcohort B1: CC-92480 with daratumumab and dexamethasone · Experimental
- Subcohort B2: CC-92480 with daratumumab and dexamethasone · Experimental
- Subcohort B3: CC-92480 with daratumumab and dexamethasone · Experimental
- Subcohort E1: CC-92480 with daratumumab and dexamethasone · Experimental
- Subcohort E2: CC-92480 with daratumumab and dexamethasone · Experimental
- Subcohort E3: CC-92480 with daratumumab and dexamethasone · Experimental
- Enrollment
- 424 (estimated)
- Primary outcomes
- Recommended Dose
- Recommended regimen as measured by dose-limiting toxicities
- Number of participants with Adverse Events (AEs)
- Overall response rate (ORR)
- Sponsor
- Celgene
- Start
- Sep 30, 2019
- Primary completion
- Nov 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03989414 · updated Nov 29, 2024